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Macrophages have been found to both promote liver fibrosis and contribute to its resolu-
tion by acquiring different phenotypes based on signals from the micro-environment. The
best-characterized phenotypes in the macrophage spectrum are labeled M1 (classically
activated) and M2 (alternatively activated). Until now the in situ localization of these phe-
notypes in diseased livers is poorly described. In this study, we therefore aimed to localize
and quantify M1- and M2-dominant macrophages in diseased mouse and human livers.The
scarred collagen-rich areas in cirrhotic human livers and in CCl4-damaged mouse livers con-
tained many macrophages. Though total numbers of macrophages were higher in fibrotic
livers, the number of parenchymal CD68-positive macrophages was significantly lower as
compared to normal. Scar-associated macrophages were further characterized as either
M1-dominant (IRF-5 and interleukin-12) or M2-dominant (CD206, transglutaminase-2, and
YM-1) and significantly higher numbers of both of these were detected in diseased livers
as compared to healthy human and mouse livers. Interestingly, in mouse, livers undergo-
ing resolution of fibrosis, the total number of CD68+ macrophages was significantly lower
compared to their fibrotic counterparts. M2-dominant (YM-1) macrophages were almost
completely gone in livers undergoing resolution, while numbers of M1-dominant (IRF-5)
macrophages were almost unchanged and the proteolytic activity (MMP9) increased. In
conclusion, this study shows the distribution of macrophage subsets in livers of both
human and murine origin. The presence of M1- and M2-dominant macrophages side by
side in fibrotic lesions suggests that both are involved in fibrotic responses, while the per-
sistence of M1-dominant macrophages during resolution may indicate their importance
in regression of fibrosis. This study emphasizes that immunohistochemical detection of
M1/M2-dominant macrophages provides valuable information in addition to widely used
flow cytometry and gene analysis.
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INTRODUCTION
Chronic injury of the liver leads to induction of fibrogenic
processes that ultimately can progress to cirrhosis, a state in
which excessive extracellular matrix deposition hampers nor-
mal liver functions. Hepatic stellate cells (HSC) are regarded
as the principal cells that are involved in scar tissue deposition
(1, 2). Recent studies indicate that the role of Kupffer cells has
been underestimated in fibrogenesis and consequently hepatic
macrophages have gained more attention recently (3–7). Kupf-
fer cells are well-known producers of reactive oxygen species,
cytokines and chemokines, that perpetuate hepatic inflammatory
responses, and of matrix-degrading enzymes. In addition, these
macrophages can phagocytose micro-organisms, apoptotic cells,
and cellular debris generated during tissue injury and remodeling.
Duffield et al. (8) clearly showed that Kupffer cells exert differ-
ent, even opposing roles during various stages of liver fibrosis.
They showed that macrophage activities during the injury phase
were predominantly associated with promotion of matrix depo-
sition and HSC activities, while during recovery macrophages
were associated with enhanced resolution and higher production
of matrix metalloproteinases (MMPs) (8, 9). These diverse roles
may indicate that activated macrophages differentiate into diverse
phenotypes during various stages of liver disease.
Activated macrophages are described to polarize into differ-
ent phenotypes depending on signals they receive from their
environment. Many types can be distinguished, and the most-
used, but rather simplified, classification system discerns classi-
cally activated macrophages (also called M1) and alternatively
activated macrophages (also called M2) (10–12). In fact, these
phenotypes represent their dominant appearance in a wide spec-
trum of overlapping activation types. Other M2-like transitional
phenotypes have been described as well, but to date these have
been difficult to distinguish from M2 macrophages in situ in
tissues due to lack of phenotype-specific markers (6, 13–15).
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In general, M1-dominant macrophages have enhanced microbi-
cidal and tumoricidal capacity and secrete high levels of pro-
inflammatory cytokines like interleukin-12 (IL-12). M1-dominant
macrophages can also inhibit fibrotic activities of fibroblasts by
releasing antifibrogenic or fibrolytic factors such as MMPs (16,
17). M2-dominant macrophages, activated by interleukin-4 and
interleukin-13, are associated with increased fibrogenesis, tissue
remodeling, and angiogenesis (17–19). In vitro, Song et al. (17)
showed that the M2-dominant macrophages produce profibro-
genic factors like platelet-derived growth factor-BB (PDGFBB)
and transforming growth factor-β (TGFbeta) and that these M2-
dominant cells increase collagen production and proliferation of
fibroblasts. Although M2 macrophages are predominantly con-
sidered to be pro-fibrotic, they are also associated with anti-
fibrotic properties, which may be explained by the different and
overlapping M2 phenotypes that exist (5, 11). For instance, M2
macrophages can also aid resolution of fibrosis by phagocytizing
apoptotic cells and matrix components via mannose and scav-
enger receptors (20–22). In addition, Pesce et al. (23) showed that
arginase-1 expressing M2 cells were related to suppression rather
than induction of fibrosis.
Thus far, most of the knowledge generated about the different
macrophage subsets is derived from in vitro studies, from flow
cytometry analyses of isolated liver macrophages (6), and from
gene analysis of liver homogenates (24). Although these techniques
generate useful quantitative information, histological detection
of macrophages gives unique and additional information with
regard to their tissue localization without selection due to iso-
lation limitations or with minor risk of missing changes because
other cells express the same markers, such as observed in tissue
homogenates (25).
How the different phenotypes are distributed in diseased
liver tissue is still largely unexplored. Therefore, we aimed to
illustrate, using immunohistochemical techniques, how different
macrophage phenotypes are distributed in situ during fibrogenic
responses and resolution of fibrosis using the general M1 and M2
classification as a starting point. Of the markers commonly used,
we chose IL-12 and IRF-5 as markers for the M1-dominant subtype
(26). Inducible nitric oxide synthase (iNOS), another commonly
used M1 marker, was not chosen because its dominant expres-
sion in hepatocytes would make distinguishing neighboring iNOS
expressing macrophages difficult (27, 28). To detect M2 polariza-
tion, we used upregulation of the mannose receptor (MRC1; also
known as CD206), transglutaminase-2 (TGM-2), and chitinase-
like secretory protein YM-1 (mouse only) (29–32). TGM-2 was
recently identified as a new human and murine M2 marker (33).
The commonly used M2 marker arginase could not be used for
reasons similar to iNOS (27).
MATERIALS AND METHODS
ANIMALS
Male mice (BALB/c,±25 g) were obtained from Harlan (Zeist, The
Netherlands) and housed in a temperature-controlled room with
12 h light/dark regimen. The animal experiments were approved
by the Institutional Animal Care and Use Committee (IACUC)
of the University of Groningen (The Netherlands) and were
performed according to strict governmental and international
guidelines on animal experimentation.
ANIMAL MODELS
Chronic liver injury (fibrosis) model
Mice received twice-weekly intraperitoneal injections of CCl4 for
4 or 8 weeks. The dose of CCl4 was gradually increased (diluted
in olive oil; week 1: 0.5 ml/kg, week 2: 0.8 ml/kg, week 3–8:
1 ml/kg). Mice were sacrificed after 4 or 8 weeks reflecting early
and advanced fibrosis, respectively.
Resolution model
Mice received CCl4 for 4 weeks (with increasing CCl4 doses as
described in the previous section). After 4 weeks, CCl4 adminis-
tration was stopped and the mice were allowed to recover for a
week after which they were sacrificed (n= 6 per group).
HUMAN LIVERS
Residual human liver tissue samples were obtained from the
Department of Hepato-Pancreato-Biliary Surgery and Liver Trans-
plantation [University Medical Center Groningen (UMCG), the
Netherlands]. At the UMCG, all patients eligible for organ trans-
plantation are asked to sign a general consent form for the
use of left-over body material (after diagnostic procedures) for
research purposes. The experimental protocols were approved by
the Medical Ethical Committee of the UMCG (Groningen) and
the anonymized tissue samples were used according to Dutch
guidelines. Normal human liver tissue (n= 7) was obtained from
residual liver tissue from donor livers discarded for transplanta-
tion because of technical reasons. Cirrhotic human liver tissue
(n= 6) was obtained from patients undergoing liver transplanta-
tion. Indications for transplantation were a.o. primary sclerosing
cholangitis (PSC), primary biliary cirrhosis (PBC), congenital cir-
rhosis, and Wilson’s cirrhosis. Although all human liver material is
anonymized, some available patient characteristics are listed below
(see Table 1).
TISSUE PROCESSING
Tissue specimens from at least three different mouse liver lobes
were snap frozen in isopentane (−80°C) for immunohistochemi-
cal analysis, or in liquid nitrogen for western blot analysis.
A wedge (10–60 g) of freshly obtained human liver was cut,
perfused with cold University of Wisconsin organ storage solu-
tion (DuPont Critical Care, Waukegan, IL, USA) immediately after
resection, and pieces were snap frozen in isopentane (−80°C).
Table 1 | Available patient characteristics of the used human livers.
Patient characteristics Normal livers Cirrhotic livers
N =7 N =6
Age (years) 41 (10–57) 49 (35–66)
Gender N =4: F N =3: F
N =2: M N =1: M
N =1: not known N =2: not known
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FIGURE 1 | Expression and localization of macrophages in normal
and fibrotic mouse livers (8 weeks CCL4). Immunohistochemical
analysis shows increased extracellular matrix deposition [collagen type I
(A,B)] and presence of macrophages [CD68 (C–F)] in fibrotic (B,D,F) as
compared to healthy livers (A,C,E). Note the increased size of certain
CD68-positive macrophages in the fibrotic areas (F) in the CCL4 livers
[arrow heads in insert (C,F)]. (G,H) Image analysis of CD68 staining.
While the total area of CD68+ cells was increased in fibrotic livers, a
significantly lower CD68-stained area was found in the parenchyma (p) of
fibrotic livers as compared to normal. Magnifications: 40× (A–D), 100×
(E,F), and 200× (inserts). f, Fibrotic matrix; p, liver parenchyma.
N =6/group. **p< 0.01.
IMMUNOHISTOCHEMICAL ANALYSIS
Acetone-fixed cryostat sections (4µm) were stained according
to standard immunohistochemical procedures with 3-amino-9-
ethyl-carbazole to detect expression of relevant markers (32).
Sections were incubated with the primary antibody for 1 h. Pri-
mary antibodies to detect fibrotic extracellular matrix (polyclonal
goat anti-collagen type I from Southern Biotech), macrophages
[mouse anti-human CD68 (DAKO), monoclonal rat anti-mouse
CD68 (AbD Serotec, Düsseldorf, Germany), and polyclonal rabbit
anti-human CD68 (Santa Cruz Biotechnology)], M1 macrophages
[polyclonal rabbit anti-human and mouse IRF-5 (Protein Tech,
Manchester, UK), goat polyclonal anti-human IL-12 p40 antibody
(ThermoScientific), and goat polyclonal anti-human and mouse
MMP9 (Santa Cruz)], and M2 macrophages [polyclonal goat anti-
mouse chitinase 3-like/ECF-L (YM-1; R&D), rabbit anti-human
TGM-2 (AbD Serotec) and CD206 (rat anti-mouse CD206 and
mouse anti-human CD206) both from BioLegends (ITK Diagnos-
tics, Uithoorn, The Netherlands)] were used. Staining of CD68
was quantified by image analysis with Cell∧D analysis program
(Olympus, Zoetermeer, The Netherlands).
To detect co-localization, we used double-staining techniques
with peroxidase and AEC (red) and alkaline phosphatase and
Naphtol AS-MX phosphate/Fast Blue BB (blue) (34). Double
stainings for IRF-5, IL-12, and CD206 were visualized with
NovaRed (red) and BCIP/NBT (blue) from Vector Laboratories.
WESTERN BLOT ANALYSIS
Tissues samples were homogenized on ice in cold RIPA buffer
[50 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 0.1% Igepal in 0.5%
sodium deoxycholate with one tablet of protease inhibitor cock-
tail and one tablet of phosphatase inhibitor (Roche Diagnos-
tics, Mannheim, Germany)] and lysates were centrifuged for 1 h
(13,000 rpm, 4°C). The supernatants were stored at −80°C. Total
protein (100µg) from each sample was applied on SDS-PAGE
(10%), transferred to polyvinylidene difluoride membranes, and
incubated overnight at 4°C with the indicated primary antibod-
ies. After washing and incubation with secondary horseradish
peroxidase-coupled antibodies, the protein bands were visual-
ized with ECL (Perkin-Elmer, Groningen, The Netherlands) and
quantified by G-Box (Syngene, Cambridge, UK).
In order to quantify the marker of interest, we corrected
the expression with the expression of the housekeeping protein
GADPH (for human samples) or β-actin (for mouse samples).
STATISTICAL ANALYSIS
Results are expressed as means± SEM. All data were analyzed with
the Mann–Whitney U test (Graph Pad software). Differences were
considered significant at p< 0.05.
RESULTS
LOCALIZATION OF CD68-POSITIVE MACROPHAGES IN HUMAN AND
MOUSE FIBROTIC LIVERS
After chronic CCl4 damage (8 weeks CCL4), pericentral necrosis
led to wound-healing responses with influx of myofibroblasts and
increased collagen deposition (Figures 1A,B) in mouse livers. As
compared to normal livers, a higher number of CD68-positive cells
was found in fibrotic livers, and these macrophages predominantly
concentrated in scars during advanced fibrosis (Figures 1C,D,G).
Furthermore, several scar-associated macrophages differed in
appearance from macrophages in normal livers, even some resem-
bled giant cells (Figures 1D,F). Remarkably, significantly less stain-
ing for CD68+ cells was found in the parenchymal areas of fibrotic
livers as compared to normal (Figures 1E–H).
Collagen deposition was also greatly increased in end-stage
human cirrhotic livers (Figures 2A,B), and a similar hepatic
distribution of macrophages as in mice was found (Figure 2).
Macrophages (CD68+) were prominently present in cirrhotic scars
irrespective of the origin of cirrhosis (Figures 2D–F). The total
number of CD68+ cells was somewhat, though not significantly,
higher in cirrhotic than normal livers (Figure 2G). Again, a trend
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FIGURE 2 | Expression and localization of macrophages in normal and
cirrhotic human livers. Immunohistochemical analysis shows enhanced
deposition of the extracellular matrix protein collagen type I (A,B) and
presence of macrophages [CD68 (C–F)] in normal (C) cirrhotic livers of various
origins [(D) PBC (E) PSC and (F) congenital cirrhosis]. Note the abundant
presence of macrophages in the collagenous fibrotic bands (F). (G,H) Image
analysis of CD68 staining in human livers. Reduced CD68 staining was found
in the parenchymal area (p) of human cirrhotic livers as compared to normal.
Magnifications: 40× (A,B) and 100× (C–F). f, fibrotic matrix; p, liver
parenchyma. N =5 cirrhotic livers, N =6 normal livers.
FIGURE 3 | Localization of IL-12 (M1) in cirrhotic human livers.
Immunohistochemical staining for IL-12p40 in cirrhotic human livers (B),
while no staining was observed in normal livers (A). (C) Co-localization of
IL-12 and CD68. Arrows indicate co-localization, f, fibrotic matrix.
Magnifications: 100× (A,B) and 400× (C). N =5 cirrhotic livers, N =6
normal livers.
toward less staining for CD68 was found in the parenchymal areas
of cirrhotic livers as compared to healthy livers (Figure 2H).
M1-DOMINANT MACROPHAGES IN MOUSE AND HUMAN LIVERS
Interleukin-12, a major cytokine produced by classically activated
macrophages, was used as an immunohistochemical marker to
detect the M1-dominant subset in the liver (Figure 3). In human
livers, higher numbers of IL-12-positive cells were detected in cir-
rhotic human livers (Figure 3B) as opposed to barely detectable
IL-12 staining in healthy livers (Figure 3A). This increased expres-
sion was confirmed by western blot analysis (Figure 4B). IL-12
positive cells were found solely in the cirrhotic collagen bands.
The staining for IL-12 co-localized completely with CD68, but
only a minor fraction of the CD68 population was positive for
IL-12 (Figure 3C).
IRF-5 was also used to identify M1 macrophages in human and
mouse livers (Figure 5). IRF-5 staining co-localized completely
with CD68 in livers of both species (Figure 5A). Similar to IL-
12, only a subset of the total number of macrophages expressed
IRF-5. To prove the phenotype-specificity of this M1 marker, we
performed double-immunostainings of IRF-5 and the M2 marker
CD206 in human livers and found little to no co-localization
(Figure 5B). Microscopic analysis showed that IRF-5 staining was
almost absent in normal mouse and human livers (Figures 5C,E).
In advanced fibrotic mouse livers, the staining was present in cells
residing in the scarred areas (Figure 5D). Similarly, in human livers
IRF-5 staining was also predominantly found in cells of the septa
(Figure 5F). Western blot analysis of liver homogenates revealed
a significantly higher expression of IRF-5 in diseased mouse and
human livers as compared to healthy livers (Figures 4A,B).
M2-DOMINANT MACROPHAGES IN MOUSE AND HUMAN LIVERS
Subsequently, we studied the hepatic distribution of alternatively
activated macrophages (Figures 6–8). CD206 is a well-known
marker for both mouse and human M2-dominant macrophages.
CD206/CD68 double-positive cells were present in fibrotic livers
and were predominantly found in scars (Figure 6A). In addition
to this, CD206 staining was present in liver parenchyma and this
staining most likely reflected expression of CD206 on sinusoidal
endothelial cells [identified with CD31 (Figure 6F)]. The pro-
nounced endothelial staining of CD206 complicates interpretation
of analyzes of whole tissue homogenates (like western blot and
mRNA expression analyses) used in the macrophage field. Micro-
scopic evaluation of sections stained for both CD206 and CD68
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FIGURE 4 | Western blot analysis of the expressions of collagen type I, IRF-5 (M1), IL-12 (M1), andYM-1 (M2) in normal and fibrotic mouse (A) and
human (B) livers. *p< 0.05. N = 5 cirrhotic human livers, N =6 normal human livers, N =4 normal mouse livers, N =6 fibrotic mouse livers.
indicated that double-positive cells were more frequent in fibrotic
liver than in normal livers, whereas western blot analysis revealed
reduced expression in both human and mouse fibrotic livers (data
not shown).
YM-1 was used as another M2 marker for mouse livers
(Figure 7). Expression of YM-1 is restricted to mice and can
therefore not be used for human liver tissue (29). YM-1 co-
localized with CD68 and with CD206 (Figures 7A,B). All cells that
expressed YM-1 were positive for CD68 and CD206, but not all
CD68-positive cells stained positive for YM-1. The hepatic expres-
sion of YM-1 was clearly higher after chronic CCl4 damage as
demonstrated by immunohistochemical staining (Figures 7C–F)
and western blot analysis (Figure 4A). YM-1 was present in the
fibrotic collagenous bands of the CCL4-damaged livers.
The recently described M2 marker TGM-2 (33) was also
used to identify M2-dominant macrophages in human livers
(Figure 8). Immunohistochemical staining for TGM-2 resulted
in staining of the parenchymal area of normal livers, mostly
staining hepatocytes, but in cirrhotic livers additional strong pos-
itive cells were found in septa (Figures 8A,B). TGM-2 staining
present in scars co-localized with CD68 (Figure 8C) and with
CD206 (Figure 8D) confirming presence of TGM-2 in hepatic M2-
dominant macrophages that accumulate in these areas. As with
iNOS, arginase-1, and CD206, quantitative evaluation of TGM-2
was confounded by its high expression in hepatocytes. We could
not detect differences between normal and cirrhotic livers (data
not shown).
M1- AND M2-DOMINANT MACROPHAGES IN A MOUSE MODEL OF
RESOLUTION
Cessation of fibrosis-inducing agents induces reversal of the
fibrotic process (35). This is also apparent in our mouse model
with lower hepatic collagen type I in livers of mice in which
CCl4 administration was stopped versus their fibrotic equivalents
(Figures 9A–C). Since macrophages are important during resolu-
tion (8, 9), we studied the localization and numbers of macrophage
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FIGURE 5 | Localization of IRF-5 (M1) in mouse and human livers.
(A) Co-localization of IRF-5 and CD68 in mouse and human livers.
(B) Double-staining for IRF-5 (blue staining) and CD206 (red staining) showed
no co-localization. (C,D) Immunohistochemical staining of IRF-5 in normal
mice livers (C) and in livers after chronic CCl4 damage (D). (E,F) IRF-5 staining
of normal (E) and cirrhotic (F) human livers. f, fibrotic matrix. Magnifications:
100× (C–F) and 400× (A,B). N =5 cirrhotic human livers, N =6 normal
human livers, N =4 normal mouse livers, N =6 fibrotic mouse livers.
FIGURE 6 | Immunohistochemical staining for CD206 (MCR-1; mannose
receptor) in human (A–C) and mouse (D,E) normal (B,D) and cirrhotic
(C,E) livers. (A) Co-localization of CD206 (blue staining) and CD68 (red
staining). Arrows indicate co-localization, asterisks indicate endothelial
staining of CD206. (F) Immunohistochemical staining for CD31 in fibrotic
mouse livers illustrating staining of sinusoidal endothelial cells.
Magnifications: 100× (B–F) and 400× (A). N =5 cirrhotic human livers, N =6
normal human livers, N =4 normal mouse livers, N =6 fibrotic mouse livers.
phenotypes in these two groups of mice. Expression of CD68 was
significantly lower in livers undergoing resolution as compared to
their fibrotic counterparts (Figures 9D–H).
We detected a slightly reduced expression of IRF-5 with both
immunohistochemical and western blot analysis (Figure 10).
However, a clear difference in the number of M2-dominant
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FIGURE 7 | Localization ofYM-1 (M2) in mouse livers. (A) Co-localization
of YM-1 (red staining) and CD68 (blue staining). (B) Co-localization of YM-1
(red staining) and CD206 (blue staining). (C–F) Immunohistochemical
localization of YM-1 in livers of normal mice (C,E) and in advanced fibrosis
(D,F). Magnifications: 40× (C,D), 200× (E,F), and 400× (A,B). N = 4
normal mouse livers, N =6 fibrotic mouse livers.
macrophages was found (Figure 11). YM-1 staining was abun-
dantly present in fibrotic livers, but in livers undergoing resolution
this M2 marker was almost completely gone. Western blot analy-
sis revealed a reduction of 81± 8% in YM-1 expression during
resolution (Figure 11E).
Since the number of IRF-5+ (M1-dominant) macrophages was
almost unchanged in fibrotic livers compared to livers undergo-
ing resolution, we measured MMP expression as a functional read
out of the presence of these macrophages. M1-dominant cells are
known to express MMP9 (17, 21, 36, 37) and western blot analy-
sis of these livers revealed significantly higher expression of MM9
92 kDa, which is known as pro-MMP9, and its processed form
(67 kDa MMP9) in the livers undergoing resolution (Figure 10F).
DISCUSSION
Recently, activation of macrophages into different phenotypes has
been subject of study in various diseases including in liver diseases.
Almost all knowledge obtained thus far is derived from in vitro
studies or from FACS or PCR analyses of tissues. These in vitro
studies have been essential to discover markers to distinguish the
various macrophages phenotypes and to identify the specific activ-
ities of these subsets. How these in vitro-generated phenotypes
relate to macrophages in situ is largely unexplored. In this study,
results were obtained from the CCL4 mouse model at several time
FIGURE 8 | LocalizationTGM-2 (M2) in human livers.
(A,B) Immunohistochemical localization of TGM-2 in normal (A) and
cirrhotic (B) human livers. Note the presence of the strongly stained cells in
the fibrotic matrix (F). (C) Co-localization of TGM-2 (blue staining) and CD68
(red staining). (D) Co-localization of TGM-2 (blue staining) and CD206 (red
staining). Arrows indicate co-localization. Magnifications: 100× (A,B) and
400× (C,D). N =5 cirrhotic human livers, N =6 normal human livers.
points in disease progression (reflecting early and advanced fibro-
sis) and resolution. Although we are aware that more time points
in this mouse model can support broader conclusions, our out-
comes with regard to the presence and localizations of the various
macrophage phenotypes are first steps toward understanding the
dynamics of macrophage phenotypes in relation to localization. A
major advantage of our studies is the verification of mouse data
in samples of human liver disease. The fact that we find similar
distributions of macrophage phenotypes in end-stage disease of
a number of different etiologies may point at converging disease
mechanisms irrespective of cause.
We used many commonly used markers M1- and M2-dominant
phenotypes and found that not all of them can be used reliably
for liver tissue. With the ones that can be used, we demonstrated
that M1- and M2-dominant subsets are localized side by side in
scars of human and mouse cirrhotic livers. Although M1 and
M2 markers can be expected to be present on the same cell,
based on the theory of overlapping spectra of macrophage sub-
sets (13–15), with our markers (IRF-5 and CD206), we found
little to no co-localization. We showed that IL-12 and IRF-
5 are useful immunohistochemical markers for M1-dominant
macrophages in liver tissue (both mouse and human) and YM-
1 for M2-dominant macrophages in murine liver tissue. CD206
and TGM-2 can be useful for immunohistochemistry of M2-
dominant macrophages in human liver tissue, but are much
less specific and therefore are hard to quantify. Furthermore,
in fibrotic livers undergoing resolution we found that M2-
dominant macrophages (YM-1 positive cells) disappeared, while
M1-dominant macrophages (IRF-5 positive cells) persisted in the
scarred areas producing MMPs.
Interleukin-12 and IRF-5 were used to identify the classically
activated macrophages in fibrotic livers. Krausgruber et al. (26)
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FIGURE 9 | Immunohistochemical and western blot analysis of the
hepatic expressions of collagen type I (A–C) and macrophages [CD68
(D–H)] in fibrosis [4 weeks of CCl4 in mice (A,D,G)] and in livers
undergoing resolution [after cessation of CCl4 administration, resolution
(B,E,H)]. **p<0.01, #p<0.1. Magnifications: 40× (A–E) and 200× (G,H).
N =6/group.
FIGURE 10 | Expressions of IRF-5 and MMP9 (M1) in fibrotic mouse livers
[4 weeks CCl4 (A,B)] and in fibrotic livers undergoing resolution [after
cessation of 4 weeks of CCl4 administration (C,D)]. Immunohistochemical
pictures demonstrate an overview [(A,C) magnification 40×] and close up
[(B,D) magnification 200×]. (E) Western blot quantification of hepatic IRF-5
expression in fibrosis versus resolution group, and (F) western blot
quantification of MMP9 expression in fibrosis versus resolution group.
A 92 kDa pro-form and a 67 kDa processed form of MMP9 is significantly
increasingly expressed in livers undergoing resolution. *p<0.05, **p< 0.01.
N =6/group.
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FIGURE 11 | Expressions ofYM-1 (M2) in fibrotic mouse livers [4 weeks
CCl4 (A,B)] and in fibrotic livers undergoing resolution [after cessation of
CCl4 administration (C,D)]. Immunohistochemical pictures demonstrate an
overview [(A,C) magnification 40×] and close up [(B,D) magnification 200×].
(E) Western blot quantification of YM-1 expression in fibrosis versus
resolution. **p<0.01. N = 6/group.
showed high expression of IRF-5 in human M1 macrophages
in culture, while M2 and non-activated macrophages did not
express IRF-5. We now show that IRF-5 can be used to iden-
tify a subset of macrophages in vivo in human and mouse livers.
Our study clearly demonstrates that M1-dominant macrophages
(CD68/IRF-5+ cells) are significantly increased in diseased liv-
ers as compared to normal. IRF-5+ cells are located in fibrous
septa in advanced fibrosis. These localizations may correspond
with reported in vitro M1 activities such as production of pro-
inflammatory cytokines and chemokines (5, 11, 17). The obser-
vation that M1-dominant macrophages are still present in livers
undergoing resolution might be related to their ability to pro-
duce MMPs (12, 16, 17, 37). Classical activation of macrophages
in vitro resulted in higher expression of MMP7 and MMP9 and
both may be necessary in the collagenous scars for removal of
collagen fibers. Indeed, in our studies we detected higher MMP9
expression in fibrotic livers undergoing resolution. In addition,
Fallowfield et al. (9) demonstrated higher hepatic MMP13 expres-
sion by scar-associated macrophages in CCL4-damaged livers and
it was found that resolution of CCl4-induced fibrosis was retarded
in MMP13-deficient mice. However, macrophage phenotypes in
these scars were not further characterized. We now show with
our localization studies that during fibrogenesis scar-associated
macrophages are both of M1- and M2-dominant phenotype, while
during resolution the scar-associated macrophages are predomi-
nantly M1 cells. It therefore appears that M1 macrophages may
also be responsible for the MMP13 production that is necessary
for resolution. Co-localization studies with IRF-5 and MMP13
may provide additional insights.
To identify M2-dominant macrophages, we started with
the well-known marker CD206 (mannose receptor, MCR-1)
(11). While in many organs M2-dominant macrophages specif-
ically express CD206, in livers CD206 expression is found in
macrophages as well as in sinusoidal endothelial cells, making
quantitative interpretations difficult. In addition, we therefore
used the well-known M2-selective marker YM-1, which does not
have this disadvantage. However, this marker is only present in
rodents (29) and cannot be used for human tissues. TGM-2 is
a novel marker for M2 macrophages recently described by us
in lungs (33). The advantage of TGM-2 is that this marker is
conserved in mice and humans. TGM-2 is a multifunctional
enzyme involved in transamidation and cross-linking of pro-
teins. It is also linked to apoptosis, cellular differentiation, and
matrix stabilization (38–40). In liver, Popov et al. (41) showed
that TGM-2 is enhanced in mice with CCl4-induced fibrosis, but
they found no relationship between TGM-2 and stabilization of
fibrotic matrix. However, TGM-2 expression was not related to
macrophage activities. Although the hepatic expression is not lim-
ited to macrophages, as can be seen in Figure 8, TGM-2 staining
in the scar-associated macrophages in cirrhotic livers is much
stronger than in other hepatic cells. Therefore, this marker can be
used for immunohistochemical stainings but quantification using
western blot or PCR will not yield useful results. To summarize,
using a combination of the markers CD206, YM-1, and TGM-2,
we are able to show that M2-dominant macrophages are present in
scar tissue during hepatic fibrogenesis. We now show that TGM-2
is co-expressed in CD68+ and in CD206+ cells in fibrotic septa in
human and mouse livers, confirming its presence in M2-dominant
hepatic macrophages.
This study clearly shows the presence of M1- and M2-dominant
macrophages side by side in fibrotic lesions in human and mouse
livers, indicating that apparently both are necessary in fibrotic
responses. At least two questions remain: (1) where do these
macrophages come from, meaning are they derived from incom-
ing monocytes and are thus bone marrow-derived or do they
develop from tissue-resident Kupffer cells that are embryonic in
origin (42). Unfortunately, our study cannot answer this ques-
tion, as there are no markers discovered yet that can reliably
distinguish bone marrow-derived from embryonic macrophages.
Previous studies showed that monocytes do infiltrate the liver
during fibrogenesis and resolution and also that Kupffer cells do
proliferate during injury (43, 44). Understanding the dynamics
of all these different macrophages during fibrogenesis/resolution
and their interactions is a subject of intense research interest.
(2) How these macrophage phenotypes interact with each other
and with other resident cells to enhance or dissolve fibrosis. Song
www.frontiersin.org September 2014 | Volume 5 | Article 430 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Beljaars et al. Localization of liver macrophage subsets
et al. (17) showed that M2-dominant macrophages increased the
proliferation index and collagen synthesis of co-cultivated WI-38
fibroblasts, while M1-dominant macrophages markedly reduced
collagen production by these cells. Most in vitro studies suggest
that M2 activation results in enhanced fibrogenesis, while M1 acti-
vation inhibits fibrogenesis through antifibrogenic or fibrolytic
factors. Just recently, Lopez-Navarrette (18) showed the impor-
tance of M2-dominant macrophages in promoting fibrogenesis in
a CCl4-induced model of liver fibrosis in which Kupffer cells were
stimulated to polarize to an M2-dominant phenotype after hepatic
inoculation of Taenia crassiceps larvae. Our results also sug-
gest a more pro-fibrotic character of M2-dominant macrophages,
because M2 markers were present in fibrotic lesions in human and
mouse livers, but were nearly absent in the livers during resolution
of fibrosis.
Recently, Ramachandran et al. (6) suggested a restorative role
for macrophages during resolution of fibrosis after cessation of
CCL4 intoxications using flow cytometry. The persistence of
M1-dominant macrophages during resolution in our studies indi-
cates that this restorative phenotype may have a more M1 bias.
M1-dominant macrophages have been reported to be major pro-
ducers of various MMPs and MMP-producing macrophages were
previously reported to be present during liver regeneration in mice
(3, 9, 16). However, M2-dominant macrophages can also express
MMPs [most notably MMP12 (45)] and were found to be impor-
tant cells for efferocytosis and phagocytosis of matrix debris (16,
21, 46–48). These characteristics of M2-dominant cells may also
be necessary during the resolution phase. The reason we do not
see M2-dominant macrophages anymore in our resolution model
may be caused by the fact that the resolution is ongoing (based
on reduced hepatic collagen deposition) and these functions of
M2-dominant macrophages may have less important. Studying
macrophage phenotype localizations at more time points during
resolution may shed more light on the specific dynamics of the
macrophage phenotypes during resolution.
In conclusion, using a set of established as well as recently iden-
tified markers we now clearly show local accumulation of both M1-
and M2-dominant macrophages in fibrotic septa of mouse and
human end-stage cirrhotic livers. This provides a basis for further
exploring the different activities of these various macrophage phe-
notypes during liver fibrosis and resolution of fibrosis. The obser-
vation that during liver remodeling M1-dominant macrophages
may persist and M2-dominant macrophages may disappear indi-
cates that different combinations of M1 versus M2-dominant
macrophages may play a key role in fibrogenesis and resolution.
Manipulation of their balance may therefore be of therapeutic
value.
ACKNOWLEDGMENTS
We gratefully acknowledge the surgeons of the Department
of Hepato-Pancreato-Biliary Surgery and Liver Transplantation
(University Medical Center Groningen, Groningen, The Nether-
lands) for providing us with healthy and cirrhotic human liver
tissue. In addition, we thank several students of Pharmacy (J. Lod-
der, K. Feenstra, L. Keyzer, E. Alons, and N. Aughsteen) for their
practical contributions to this paper.
REFERENCES
1. Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diag-
nosis and management. J Hepatol (2005) 42(Suppl 1):S22–36. doi:10.1016/j.
jhep.2004.12.008
2. Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol
Hepatol (2010) 7(8):425–36. doi:10.1038/nrgastro.2010.97
3. Ramachandran P, Iredale JP. Macrophages: central regulators of hepatic fibroge-
nesis and fibrosis resolution. J Hepatol (2012) 56(6):1417–9. doi:10.1016/j.jhep.
2011.10.026
4. Heymann F, Trautwein C, Tacke F. Monocytes and macrophages as cellu-
lar targets in liver fibrosis. Inflamm Allergy Drug Targets (2009) 8(4):307–18.
doi:10.2174/187152809789352230
5. Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibro-
sis. Semin Liver Dis (2010) 30(3):245–57. doi:10.1055/s-0030-1255354
6. Ramachandran P, Pellicoro A, Vernon MA, Boulter L, Aucott RL, Ali A, et al.
Differential Ly-6C expression identifies the recruited macrophage phenotype,
which orchestrates the regression of murine liver fibrosis. Proc Natl Acad Sci U
S A (2012) 109(46):E3186–95. doi:10.1073/pnas.1119964109
7. Sica A, Invernizzi P, Mantovani A. Macrophage plasticity and polarization in liver
homeostasis and pathology. Hepatology (2014) 59(5):2034–42. doi:10.1002/hep.
26754
8. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, et al.
Selective depletion of macrophages reveals distinct, opposing roles during liver
injury and repair. J Clin Invest (2005) 115(1):56–65. doi:10.1172/JCI22675
9. Fallowfield JA, Mizuno M, Kendall TJ, Constandinou CM, Benyon RC, Duffield
JS, et al. Scar-associated macrophages are a major source of hepatic matrix
metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis.
J Immunol (2007) 178(8):5288–95. doi:10.4049/jimmunol.178.8.5288
10. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and
functions. Immunity (2010) 32(5):593–604. doi:10.1016/j.immuni.2010.05.007
11. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine
system in diverse forms of macrophage activation and polarization. Trends
Immunol (2004) 25(12):677–86. doi:10.1016/j.it.2004.09.015
12. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polar-
ization. Front Biosci (2008) 13:453–61. doi:10.2741/2692
13. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation.
Nat Rev Immunol (2008) 8(12):958–69. doi:10.1038/nri2448
14. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage plasticity
and polarization in tissue repair and remodelling. J Pathol (2013) 229(2):176–85.
doi:10.1002/path.4133
15. Mills CD, Ley K. M1 and M2 macrophages: the chicken and the egg of immunity.
J Innate Immun (2014). doi:10.1159/000364945
16. Huang WC, Sala-Newby GB, Susana A, Johnson JL, Newby AC. Classical
macrophage activation up-regulates several matrix metalloproteinases through
mitogen activated protein kinases and nuclear factor-kappaB. PLoS One (2012)
7(8):e42507. doi:10.1371/journal.pone.0042507
17. Song E, Ouyang N, Horbelt M, Antus B, Wang M, Exton MS. Influence of alter-
natively and classically activated macrophages on fibrogenic activities of human
fibroblasts. Cell Immunol (2000) 204(1):19–28. doi:10.1006/cimm.2000.1687
18. Lopez-Navarrete G, Ramos-Martinez E, Suarez-Alvarez K, Aguirre-Garcia J,
Ledezma-Soto Y, Leon-Cabrera S, et al. Th2-associated alternative Kupffer cell
activation promotes liver fibrosis without inducing local inflammation. Int J Biol
Sci (2011) 7(9):1273–86. doi:10.7150/ijbs.7.1273
19. Gibbons M, MacKinnon A, Ramachandran P, Dhaliwal K, Duffin R, Phythian-
Adams A, et al. Ly6Chi monocytes direct alternatively activated profibrotic
macrophage regulation of lung fibrosis. Am J Respir Crit Care Med (2011)
184(5):569–81. doi:10.1164/rccm.201010-1719OC
20. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for
fibrotic disease. Nat Med (2012) 18(7):1028–40. doi:10.1038/nm.2807
21. Boorsma CE, Draijer C, Melgert BN. Macrophage heterogeneity in respiratory
diseases. Mediators Inflamm (2013) 769214:19. doi:10.1155/2013/769214
22. Lopez-Guisa JM, Cai X, Collins SJ, Yamaguchi I, Okamura DM, Bugge TH,
et al. Mannose receptor 2 attenuates renal fibrosis. J Am Soc Nephrol (2012)
23(2):236–51. doi:10.1681/ASN.2011030310
23. Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC, Smith
AM, et al. Arginase-1-expressing macrophages suppress Th2 cytokine-driven
inflammation and fibrosis. PLoS Pathog (2009) 5(4):e1000371. doi:10.1371/
journal.ppat.1000371
Frontiers in Immunology | Molecular Innate Immunity September 2014 | Volume 5 | Article 430 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Beljaars et al. Localization of liver macrophage subsets
24. Louvet A, Teixeira-Clerc F, Chobert MN, Deveaux V, Pavoine C, Zimmer A,
et al. Cannabinoid CB2 receptors protect against alcoholic liver disease by reg-
ulating Kupffer cell polarization in mice. Hepatology (2011) 54(4):1217–26.
doi:10.1002/hep.24524
25. Randolph GJ. Proliferating macrophages prevail in atherosclerosis. Nat Med
(2013) 19(9):1094–5. doi:10.1038/nm.3316
26. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N, et al. IRF5
promotes inflammatory macrophage polarization and TH1-TH17 responses.
Nat Immunol (2011) 12(3):231–8. doi:10.1038/ni.1990
27. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M,
et al. Towards a knowledge-based human protein atlas. Nat Biotechnol (2010)
28(12):1248–50. doi:10.1038/nbt1210-1248
28. Vos TA, Van Goor H, Tuyt L, De Jager-Krikken A, Leuvenink R, Kuipers F, et al.
Expression of inducible nitric oxide synthase in endotoxemic rat hepatocytes is
dependent on the cellular glutathione status. Hepatology (1999) 29(2):421–6.
doi:10.1002/hep.510290231
29. Raes G, Van den Bergh R, De Baetselier P, Ghassabeh GH, Scotton C, Locati M,
et al. Arginase-1 and Ym1 are markers for murine, but not human, alternatively
activated myeloid cells. J Immunol (2005) 174(11):6561. doi:10.4049/jimmunol.
174.11.6561
30. Raes G, De Baetselier P, Noel W, Beschin A, Brombacher F, Hassanzadeh Gh
G. Differential expression of FIZZ1 and Ym1 in alternatively versus classically
activated macrophages. J Leukoc Biol (2002) 71(4):597–602.
31. Van Gorp H, Delputte PL, Nauwynck HJ. Scavenger receptor CD163, a Jack-
of-all-trades and potential target for cell-directed therapy. Mol Immunol (2010)
47(7–8):1650–60. doi:10.1016/j.molimm.2010.02.008
32. Melgert BN, ten Hacken NH, Rutgers B, Timens W, Postma DS, Hylkema MN.
More alternative activation of macrophages in lungs of asthmatic patients.
J Allergy Clin Immunol (2011) 127(3):831–3. doi:10.1016/j.jaci.2010.10.045
33. Martinez FO, Helming L, Milde R, Varin A, Melgert BN, Draijer C, et al. Genetic
programs expressed in resting and IL-4 alternatively activated mouse and
human macrophages: similarities and differences. Blood (2013) 121(9):e57–69.
doi:10.1182/blood-2012-06-436212
34. Beljaars L, Molema G, Weert B, Bonnema H, Olinga P, Groothuis GM, et al.
Albumin modified with mannose 6-phosphate: a potential carrier for selective
delivery of antifibrotic drugs to rat and human hepatic stellate cells. Hepatology
(1999) 29(5):1486–93. doi:10.1002/hep.510290526
35. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflam-
mation and repair in a solid organ. J Clin Invest (2007) 117(3):539–48.
doi:10.1172/JCI30542
36. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage sub-
sets. Nat Rev Immunol (2011) 11(11):723–37. doi:10.1038/nri3073
37. Hanania R, Sun HS, Xu K, Pustylnik S, Jeganathan S, Harrison RE. Classically
activated macrophages use stable microtubules for matrix metalloproteinase-
9 (MMP-9) secretion. J Biol Chem (2012) 287(11):8468–83. doi:10.1074/jbc.
M111.290676
38. Belkin AM. Extracellular TG2: emerging functions and regulation. FEBS J (2011)
278(24):4704–16. doi:10.1111/j.1742-4658.2011.08346.x
39. Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with
diverse functions. Trends Biochem Sci (2002) 27(10):534–9. doi:10.1016/S0968-
0004(02)02182-5
40. Fesus L, Szondy Z. Transglutaminase 2 in the balance of cell death and survival.
FEBS Lett (2005) 579(15):3297–302. doi:10.1016/j.febslet.2005.03.063
41. Popov Y, Sverdlov DY, Sharma AK, Bhaskar KR, Li S, Freitag TL, et al. Tissue
transglutaminase does not affect fibrotic matrix stability or regression of liver
fibrosis in mice. Gastroenterology (2011) 140(5):1642–52. doi:10.1053/j.gastro.
2011.01.040
42. Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, et al.
Dendritic cells, monocytes and macrophages: a unified nomenclature based on
ontogeny. Nat Rev Immunol (2014) 14(8):571–8. doi:10.1038/nri3712
43. Liaskou E, Zimmermann HW, Li KK, Oo YH, Suresh S, Stamataki Z,
et al. Monocyte subsets in human liver disease show distinct phenotypic and
functional characteristics. Hepatology (2013) 57(1):385–98. doi:10.1002/hep.
26016
44. Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibro-
sis. J Hepatol (2014) 60(5):1090–6. doi:10.1016/j.jhep.2013.12.025
45. Nelson MP, Christmann BS, Dunaway CW, Morris A, Steele C. Experimen-
tal pneumocystis lung infection promotes M2a alveolar macrophage-derived
MMP12 production. Am J Physiol Lung Cell Mol Physiol (2012) 303(5):L469–75.
doi:10.1152/ajplung.00158.2012
46. Madala SK, Pesce JT, Ramalingam TR, Wilson MS, Minnicozzi S, Cheever
AW, et al. Matrix metalloproteinase 12-deficiency augments extracellular
matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis.
J Immunol (2010) 184(7):3955–63. doi:10.4049/jimmunol.0903008
47. Dalli J, Serhan CN. Specific lipid mediator signatures of human phagocytes:
microparticles stimulate macrophage efferocytosis and pro-resolving mediators.
Blood (2012) 120(15):e60–72. doi:10.1182/blood-2012-04-423525
48. Morimoto K, Janssen WJ, Terada M. Defective efferocytosis by alveolar
macrophages in IPF patients. Respir Med (2012) 106(12):1800–3. doi:10.1016/j.
rmed.2012.08.020
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 10 July 2014; paper pending published: 02 August 2014; accepted: 22 August
2014; published online: 08 September 2014.
Citation: Beljaars L, Schippers M, Reker-Smit C, Martinez FO, Helming L, Poelstra K
and Melgert BN (2014) Hepatic localization of macrophage phenotypes during fibro-
genesis and resolution of fibrosis in mice and humans. Front. Immunol. 5:430. doi:
10.3389/fimmu.2014.00430
This article was submitted to Molecular Innate Immunity, a section of the journal
Frontiers in Immunology.
Copyright © 2014 Beljaars, Schippers, Reker-Smit , Martinez, Helming , Poelstra and
Melgert . This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
www.frontiersin.org September 2014 | Volume 5 | Article 430 | 11
